NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 973.3 DKK | -0.71% |
|
-1.15% | +39.42% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
973.3
DKK
Average target price
956.5
DKK
Spread / Average Target
-1.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +39.42% | 631B | |
| +63.05% | 856B | |
| -4.78% | 359B | |
| +17.52% | 325B | |
| +8.43% | 297B | |
| +14.19% | 244B | |
| +5.81% | 234B | |
| +16.77% | 226B | |
| +14.63% | 177B | |
| +1.08% | 165B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk's Ozempic Reduces Dementia and Cognitive Risks, Oxford Study Says
